- Status:
- Topic selection
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Further information:
- The NICE-Wide Prioritisation Board met on 26 March 2025 and concluded that an evaluation would not be appropriate for this product. The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate your products is due to the existing NHSE policy in place which recommends use of doravirine in combination with other drugs for the treatment of HIV-1 in adults. The board felt that that an update to this commissioning policy would be more appropriate. The NICE-Wide Prioritisation Board (PB) met on 19 May 2025 to reconsider the non-selection decision that was agreed in January 2025. After careful deliberation, the Board confirmed that the original non-selection decision made in January 2025 remains appropriate, and that doravirine–islatravir should not be selected for evaluation.
Project Team
- Project lead
- Danielle Lees
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 April 2025 | Topic selection |
For further information on how we select topics for development, please see our page about prioritising our guidance topics